Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Clanotech Receives Orphan Drug Designation in the EU

October 20, 2014 10:48 am | News | Comments

Clanotech AB announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency (EMA) for prevention of scarring post glaucoma filtration surgery.  Read more...

TOPICS:

NewLink Genetics, Genentech Enter Into Exclusive Worldwide License

October 20, 2014 10:44 am | News | Comments

NewLink Genetics Corp., a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced that they have entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development of NLG919, NewLink's IDO pathway inhibitor. Read more...

TOPICS:

Sanofi, Regeneron Announce Phase 3 Study of Atopic Dermatitis Drug

October 20, 2014 10:32 am | News | Comments

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. Read more..

TOPICS:
Advertisement

Takeda, Orexigen Announce Availability of Weight-Management Drug

October 20, 2014 10:25 am | News | Comments

Takeda and Orexigen jointly announced that Contrave (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Read more...                 

TOPICS:

Drug Restores Pleasure-Seeking Ahead of Other Antidepressant Effects

October 20, 2014 10:14 am | News | Comments

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of — and ahead of — its other antidepressant effects, in an NIH trial. Within 40 minutes after a single infusion of ketamine, treatment-resistant depressed bipolar disorder patients experienced a reversal of a key symptom — loss of interest in pleasurable activities — which lasted up to 14 days. Read more...

TOPICS:

EU Seeking to Create $1.27B Ebola Fund

October 20, 2014 9:47 am | by Raf Casert | News | Comments

European Union nations are working to reach 1 billion euros ($1.27 billion) in aid by the end of the week to fight Ebola in West Africa and are seeking a common approach to the crisis. Read more...

TOPICS:

U.S. Monitors Health Care Worker Aboard Cruise Ship

October 17, 2014 1:43 pm | by Jim Kuhnhenn | News | Comments

A cruise ship with a Dallas health care worker aboard who is being monitored for signs of Ebola did not receive clearance to dock in Cozumel, Mexico, a day after Belize refused to let the passenger leave the vessel. Read more...

TOPICS:

Chimerix Gets FDA OK to Test Drug for Ebola

October 17, 2014 1:34 pm | News | Comments

A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration. Read more...

TOPICS:
Advertisement

AbbVie Announces Results for HS Treatment

October 17, 2014 1:21 pm | News | Comments

AbbVie announced new results from PIONEER 2, a pivotal Phase 3 study, demonstrating the effect of Humira (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. Read more...

TOPICS:

UCSF, CDRD Sign Drug Development Agreement

October 17, 2014 1:06 pm | News | Comments

UCSFo and CDRD, a non-profit drug development center headquartered in Vancouver, Canada, announced a collaborative affiliation to identify potential medications and develop them to the stage where they are commercially attractive to private sector partners. Read more...

TOPICS:

Amgen Files Lawsuit Against Sanofi, Regeneron for Patent Infringement

October 17, 2014 12:57 pm | News | Comments

Amgen announced that it filed a lawsuit against Sanofi and Regeneron Pharmaceuticals, Inc. for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. Read more...

TOPICS:

UN: We botched response to the Ebola outbreak

October 17, 2014 11:15 am | by Maria Cheng - AP Medical Writer - Associated Press | News | Comments

The World Health Organization has admitted that it botched attempts to stop the now-spiraling Ebola outbreak in West Africa, blaming factors including incompetent staff and a lack of information. Read more...

TOPICS:

Anoro's COPD Drug Shows Improved Lung Function

October 17, 2014 11:07 am | News | Comments

Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta. Read more...                                     

TOPICS:

Pharmacyclics' Non-Chemo Treatment Approved in Europe

October 17, 2014 10:54 am | News | Comments

Pharmacyclics Inc. announced that the European Commission (EC) has granted marketing approval for Imbruvica (ibrutinib) throughout the 28 member states of the European Union (EU). Imbruvica, a first-in-class, oral, once-daily, non-chemotherapy treatment, now is approved to be marketed in Europe. Read more...

TOPICS:

A Look At Latest Ebola Developments

October 17, 2014 10:40 am | News | Comments

The nation's top health officials tried to assure Congress that they can halt the spread of the Ebola virus in the U.S. despite mistakes that allowed two nurses to get the infection from a patient. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading